Stichting MelanomaSarcomaGroningana

Publicaties

Sloot S, Fedorenko IV, Smalley KS, Gibney GT. Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe? Expert Opin Pharmacother. 2014 Apr;15(5):589-92.

Bosscher MR, van Leeuwen BL, Hoekstra HJ. Surgical emergencies in oncology. Cancer Treat Rev. 2014 Sep;40(8):1028-36.

Sloot S, Rashid OM, Zager JS. Regional therapy in metastatic melanoma: an update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion. Expert Opin Drug Metab Toxicol. 2014 Oct;10(10):1355-64

Sloot S, Rashid OM, Zager JS. Intralesional therapy for metastatic melanoma. Expert Opin Pharmacother. 2014 Dec;15(18):2629-39.

Paraiso KH, Das Thakur M, Fang B, Koomen JM, Fedorenko IV, John JK, Tsao H, Flaherty KT, Sondak VK, Messina JL, Pasquale EB, Villagra A, Rao UN, Kirkwood JM, Meier F, Sloot S, Gibney GT, Stuart D, Tawbi H, Smalley KS. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov. 2015 Mar;5(3):264-73

Ahmed KA, Freilich JM, Sloot S, Figura N, Gibney GT, Weber JS, Sarangkasiri S, Chinnaiyan P, Forsyth PA, Etame AB, Rao NG. LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. J Neurooncol. 2015 Mar;122(1):121-6

Speijers MJ, Bastiaannet E, Sloot S, Suurmeijer AJ, Hoekstra HJ. Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients. Ann Surg Oncol. 2015 Sep;22(9):2978-87.

Holtkamp LH, Wang S, Wilmott JS, Madore J, Vilain R, Thompson JF, Nieweg OE, Scolyer RA. Detailed pathological examination of completion node dissection specimens and outcome in melanoma patients with minimal (<0.1 mm) sentinel lymph node metastases. Ann Surg Oncol. 2015 Sep;22(9):2972-7

Bosscher MR, Bastiaannet E, van Leeuwen BL, Hoekstra HJ Current management of surgical oncologic emergencies. PLoS One. 2015;10(5):e0124641.

Speijers MJ, Bastiaannet E, Sloot S, Suurmeijer AJ, Hoekstra HJ.Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients. Ann Surg Oncol. 2015;22(9):2978-87.

Sloot S, Zager JS, Kudchadkar RR, Messina JL, Benedict JJ, Gonzalez RJ, DeConti R, Turner LM, McCardle T, Smalley KS, Weber JS, Sondak VK, Gibney GT. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy. Melanoma Res. 2016 Feb;26(1):83-7.

Bosscher MR, Bastiaannet E, van Leeuwen BL, Hoekstra HJ. Factors Associated with Short-Term Mortality After Surgical Oncologic Emergencies. Ann Surg Oncol. 2016;23(6):1803-14

Damude S, Hoekstra HJ, Bastiaannet E, Muller Kobold AC, Kruijff S, Wevers KP. The predictive power of serum S-100B for non-sentinel node positivity in melanoma patients. Eur J Surg Oncol. 2016;42(4):545-51.

Damude S, Niebling MG, Kobold AC, Hoekstra HJ, Kruijff S, Wevers KP. Adipocytes in venipunctures cause falsely elevated S-100B serum values. Clin Chem Lab Med. 2016;54(8):e235-7.

Sloot S, Speijers MJ, Bastiaannet E, Hoekstra HJ. Is there a relation between type of primary melanoma treatment and the development of intralymphatic metastasis? A review of the literature.Cancer Treat Rev. 2016; 45:120-8.

Damude S, Hoekstra-Weebers JE, Francken AB, Ter Meulen S, Bastiaannet E, Hoekstra HJ. The MELFO-Study: Prospective, Randomized, Clinical Trial for the Evaluation of a Stage-adjusted Reduced Follow-up Schedule in Cutaneous Melanoma Patients-Results after 1 Year. Ann Surg Oncol. 2016;23(9):2762-71

Slump J, Ferguson PC, Wunder JS, Griffin A, Hoekstra HJ, Bagher S, Zhong T, Hofer SO, O’Neill AC. Can the ACS-NSQIP surgical risk calculator predict post-operative complications in patients undergoing flap reconstruction following soft tissue sarcoma resection? J Surg Oncol. 2016;114(5):570-575.

Sloot S, Rashid OM, Sarnaik AA, Zager JS. Developments in Intralesional Therapy for Metastatic Melanoma. Cancer Control. 2016; 23(1):12-20. Review.

Sloot S, Zager JS, Kudchadkar RR, Messina JL, Benedict JJ, Gonzalez RJ, DeConti R, Turner LM, McCardle T, Smalley KS, Weber JS, Sondak VK, Gibney GT. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy. Melanoma Res. 2016;26(1):83-7.

Holtkamp LHJ, Read RL, Emmett L, Thompson JF, Nieweg OE. Futility of imaging to stage melanoma patients with a positive sentinel lymph node. Melanoma Res. 2017t;27(5):457-462.

Stevenson M.G., Musters AH, Geertzen JHB, van Leeuwen BL, Hoekstra HJ, Been LB. Amputations for extremity soft tissue sarcoma in an era of limb salvage treatment: Local control and survival. J Surg Oncol. 2018 ;117(3):434-442

Verstijnen J, Damude S, Hoekstra HJ, Kruijff S, Ten Tije AJ, Louwman WJ, Bastiaannet E, Stuiver MM. Practice variation in Sentinel Lymph Node Biopsy for melanoma patients in different geographical regions in the Netherlands. Surg Oncol. 2017; 26:431-437.

Slump J, Ferguson PC, Wunder JS, Griffin AM, Hoekstra HJ, Liu X, Hofer SOP, O’Neill AC. Patient, tumour and treatment factors affect complication rates in soft tissue sarcoma flap reconstruction in a synergistic manner. Eur J Surg Oncol. 2017 Jun;43(6):1126-1133.

Damude S, Hoekstra-Weebers JEHM, van Leeuwen BL, Hoekstra HJ. Melanoma patients’ disease-specific knowledge, information preference, and appreciation of educational YouTube videos for self-inspection. Eur J Surg Oncol. 2017 43(8):1528-1535.

Damude S, Wevers KP, Murali R, Kruijff S, Hoekstra HJ, Bastiaannet E. A prediction tool incorporating the biomarker S-100B for patient selection for completion lymph node dissection in stage III melanoma. Eur J Surg Oncol. 2017;43(9):1753-1759.

Stevenson M.G., Hoekstra HJ, Song W, Suurmeijer AJH, Been LB.  Histopathological tumor response following neoadjuvant hyperthermic isolated limb perfusion in extremity soft tissue sarcomas: Evaluation of the EORTC-STBSG response score. Eur J Surg Oncol. 2018 Sep;44(9):1406-1411.

Stevenson M.G., Been LB, Hoekstra HJ, Suurmeijer AJH, Boellaard R, Brouwers AH. Volume of interest delineation techniques for 18F-FDG PET-CT scans during neoadjuvant extremity soft tissue sarcoma treatment in adults: a feasibility study. EJNMMI Res. 2018 Jun 7;8(1):42.

Stevenson M.G., Ubbels JF, Slump J, Huijing MA, Bastiaannet E, Pras E, Hoekstra HJ, Been LB. Identification of predictors for wound complications following preoperative or postoperative radiotherapy in extremity soft tissue sarcoma.Eur J Surg Oncol. 2018 Jun;44(6):816-822.

Slump J, Hofer SOP, Ferguson PC, Wunder JS, Griffin AM, Hoekstra HJ, Bastiaannet E, O’Neill AC. Flap choice does not affect complication rates or functional outcomes following extremity soft tissue sarcoma reconstruction. J Plast Reconstr Aesthet Surg. 2018 Jul;71(7):989-996.

Stevenson M.G., Seinen JM, Pras E, Brouwers AH, van Ginkel RJ, van Leeuwen BL, Suurmeijer AJH, Been LB, Hoekstra HJ. Hyperthermic isolated limb perfusion, preoperative radiotherapy, and surgery (PRS) a new limb saving treatment strategy for locally advanced sarcomas. J Surg Oncol. 2018 Jun;117(7):1447-1454.

Slump J, Bastiaannet E, Halka A, Hoekstra HJ, Ferguson PC, Wunder JS, Hofer SOP, O’Neill AC. Risk factors for postoperative wound complications after extremity soft tissue sarcoma resection: A systematic review and meta-analyses. J Plast Reconstr Aesthet Surg. 2019 Sep;72(9):1449-1464.

Deckers EA, Wevers KP, Muller Kobold AC, Damude S, Vrielink OM, van Ginkel RJ, Been LB, van Leeuwen BL, Hoekstra HJ, Kruijff S.  S-100B as an extra selection tool for FDG PET/CT scanning in follow-up of AJCC stage III melanoma patients. J Surg Oncol. 2019;120(6):1031-1037.

Damude S, Muller Kobold AC, Bastiaannet E, Kruijff S, Hoekstra HJ, Wevers KP. Double venipuncture is not required for adequate S-100B determination in melanoma patients. Biotechniques. 2020;69(5):371-378.

Deckers EA, Hoekstra-Weebers JEHM, Damude S, Francken AB, Ter Meulen S, Bastiaannet E, Hoekstra HJ. The MELFO Study: A Multicenter, Prospective, Randomized Clinical Trial on the Effects of a Reduced Stage-Adjusted Follow-Up Schedule on Cutaneous Melanoma IB-IIC Patients-Results After 3 Years. Ann Surg Oncol. 2020;27(5):1407-1417.

Deckers EA, Kruijff S, Brouwers AH, van der Steen K, Hoekstra HJ, Thompson JF, Vállez García D, Wevers KP. The association between active tumor volume, total lesion glycolysis and levels of S-100B and LDH in stage IV melanoma patients. Eur J Surg Oncol. 2020 Nov;46(11):2147-2153

Francken AB, Hoekstra-Weebers JEHM, Deckers EA, Hoekstra HJ. ASO Author Reflections: Stage-Adjusted Reduced Follow-Up of Melanoma Patients is Justified and Cost Effective, Until Biomarkers to Predict Prognosis Have Been Identified. Ann Surg Oncol. 2020 May;27(5):1418-1419

Deckers EA, Wj Louwman M, Kruijff S, Hoekstra HJ. Letter in reply: increase of sentinel lymph node melanoma staging in The Netherlands; still room and need for further improvement. Melanoma Manag. 2020 Nov 23;8(1):MMT53.

Proefschriften

Dr. M.R.F. Bosscher. Surgical Oncologic Emergencies. Decision Making and Clinical Outcome. RUG 21-09-2015

Dr. S. Sloot Developments in the treatment of advanced melanoma. RUG 22-11-2017

Dr. J. Slump The role of reconstructive surgery in the treatment of soft tissue sarcomas. 24-09- 2018

Dr. M.G. Stevenson Localized extremity soft tissue sarcoma: towards a patient-tailored approach. RUG 08-10-2018

Dr. S. Damude Melanoma New Insights in Follow-up & Staging. RUG 28-11-2018

Dr. E.A. Deckers Melanoma; The Impact of Staging on Treatment, Prognosis & Follow-up. RUG, 20-04-2020